Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Open in API
Filings indexed 274 across all filing types
Latest filing 2025-06-05 Regulatory Filings
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release (“For Immediate Release”) announcing the closing of an asset sale and plans for facility expansion. It does not present financial results (ER/IR), is not an investor presentation (IP), not an annual or interim report, not an earnings release, nor a notice of dividend, governance change, M&A takeover bid, or share transaction. It is a general corporate news announcement and thus falls into the fallback “Regulatory Filings” category (RNS).
2025-06-05 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the start of production under a distribution agreement, with no attached financial report, no vote results, no management changes, no earnings data, and no proxy materials. It is not a formal report (e.g., 10-K, IR, ER) but rather a general business update. It therefore falls into the fallback category “Regulatory Filings” (RNS).
2025-05-26 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing that all conditions precedent have been removed for the proposed $4.5 million sale of the Hope Facility, on track to close in June. It is not reporting quarterly results (not an Earnings Release), nor is it a merger/takeover bid document (M&A is for proposals or bids), and it is not about share issuance or buybacks. Instead, it is an update on a cash-generating transaction (asset sale) that affects the company’s capital/financing position. Therefore, it best fits the Capital/Financing Update category.
2025-05-22 English
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a news release by MediPharm Labs ahead of its Annual and Special Meeting of Shareholders, explicitly urging shareholders to vote using the GREEN proxy in support of the company’s board nominees. It details proxy voting instructions and addresses a dissident proxy solicitation by Apollo, which is characteristic of proxy solicitation materials. Therefore, it falls under Proxy Solicitation & Information Statement (Code: PSI).
2025-05-21 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the date and details for the upcoming first quarter 2025 financial results release and related conference call/webcast. It does not include any actual financial results or detailed data. This fits the definition of a Report Publication Announcement (RPA) since it is purely notifying investors of the timing of a forthcoming report rather than presenting the results themselves.
2025-05-09 English
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a PR news release responding to a dissident proxy circular and urging shareholders to take no action ahead of the upcoming Annual and Special Meeting. It provides arguments around board nominations and indicates that a detailed Management Information Circular (proxy statement) will be filed. This communication is clearly part of the proxy solicitation process—providing information to shareholders and seeking to influence their votes—which aligns with the definition of Proxy Solicitation & Information Statement (Code: PSI), rather than being an actual annual report, earnings release, or regulatory-filing announcement.
2025-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.